Eintrag weiter verarbeiten
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
Gespeichert in:
| Zeitschriftentitel: | Oxford Medical Case Reports |
|---|---|
| Personen und Körperschaften: | |
| In: | Oxford Medical Case Reports, 2020, 2020, 1 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
Palazzo, Giovanni Palazzo, Giovanni |
|---|---|
| author |
Palazzo, Giovanni |
| spellingShingle |
Palazzo, Giovanni Oxford Medical Case Reports Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris Infectious Diseases Microbiology Parasitology |
| author_sort |
palazzo, giovanni |
| spelling |
Palazzo, Giovanni 2053-8855 Oxford University Press (OUP) Infectious Diseases Microbiology Parasitology http://dx.doi.org/10.1093/omcr/omz134 <jats:title>Abstract</jats:title> <jats:p>Plaque psoriasis is a chronic debilitating condition, and biologic agents that inhibit tumor necrosis factor-α (TNF-α) are widely employed in management of the condition. Notwithstanding, several paradoxical adverse reactions have been reported with TNF-α inhibitors, including vasculitis, vitiligo, alopecia areata, sarcoidosis and other granulomatous diseases. Herein, we report the case of a 63-year-old man who developed vitiligo while on therapy with adalimumab following failure of conventional agents for plaque psoriasis. After discontinuation of adalimumab and initiation of secukinumab, vitiligo and other psoriatic symptoms gradually resolved. After 1 year of treatment, only small plaque areas were present in the flexor site with complete remission in the extensor area along with near complete resolution of depigmented areas. In this case of possible adalimumab-induced vitiligo in a patient with plaque psoriasis, secukinumab resolved both the symptoms of psoriasis and the likely adalimumab-related vitiligo.</jats:p> Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris Oxford Medical Case Reports |
| doi_str_mv |
10.1093/omcr/omz134 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9vbWNyL29tejEzNA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9vbWNyL29tejEzNA |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Oxford University Press (OUP), 2020 |
| imprint_str_mv |
Oxford University Press (OUP), 2020 |
| issn |
2053-8855 |
| issn_str_mv |
2053-8855 |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
palazzo2020resolutionofpostadalimumabvitiligowithsecukinumabinapatientwithpsoriasisvulgaris |
| publishDateSort |
2020 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
Oxford Medical Case Reports |
| source_id |
49 |
| title |
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_unstemmed |
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_full |
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_fullStr |
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_full_unstemmed |
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_short |
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_sort |
resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| topic |
Infectious Diseases Microbiology Parasitology |
| url |
http://dx.doi.org/10.1093/omcr/omz134 |
| publishDate |
2020 |
| physical |
|
| description |
<jats:title>Abstract</jats:title>
<jats:p>Plaque psoriasis is a chronic debilitating condition, and biologic agents that inhibit tumor necrosis factor-α (TNF-α) are widely employed in management of the condition. Notwithstanding, several paradoxical adverse reactions have been reported with TNF-α inhibitors, including vasculitis, vitiligo, alopecia areata, sarcoidosis and other granulomatous diseases. Herein, we report the case of a 63-year-old man who developed vitiligo while on therapy with adalimumab following failure of conventional agents for plaque psoriasis. After discontinuation of adalimumab and initiation of secukinumab, vitiligo and other psoriatic symptoms gradually resolved. After 1 year of treatment, only small plaque areas were present in the flexor site with complete remission in the extensor area along with near complete resolution of depigmented areas. In this case of possible adalimumab-induced vitiligo in a patient with plaque psoriasis, secukinumab resolved both the symptoms of psoriasis and the likely adalimumab-related vitiligo.</jats:p> |
| container_issue |
1 |
| container_start_page |
0 |
| container_title |
Oxford Medical Case Reports |
| container_volume |
2020 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792340257617739778 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:01:09.581Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Resolution+of+post-adalimumab+vitiligo+with+secukinumab+in+a+patient+with+psoriasis+vulgaris&rft.date=2020-01-31&genre=article&issn=2053-8855&volume=2020&issue=1&jtitle=Oxford+Medical+Case+Reports&atitle=Resolution+of+post-adalimumab+vitiligo+with+secukinumab+in+a+patient+with+psoriasis+vulgaris&aulast=Palazzo&aufirst=Giovanni&rft_id=info%3Adoi%2F10.1093%2Fomcr%2Fomz134&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792340257617739778 |
| author | Palazzo, Giovanni |
| author_facet | Palazzo, Giovanni, Palazzo, Giovanni |
| author_sort | palazzo, giovanni |
| container_issue | 1 |
| container_start_page | 0 |
| container_title | Oxford Medical Case Reports |
| container_volume | 2020 |
| description | <jats:title>Abstract</jats:title> <jats:p>Plaque psoriasis is a chronic debilitating condition, and biologic agents that inhibit tumor necrosis factor-α (TNF-α) are widely employed in management of the condition. Notwithstanding, several paradoxical adverse reactions have been reported with TNF-α inhibitors, including vasculitis, vitiligo, alopecia areata, sarcoidosis and other granulomatous diseases. Herein, we report the case of a 63-year-old man who developed vitiligo while on therapy with adalimumab following failure of conventional agents for plaque psoriasis. After discontinuation of adalimumab and initiation of secukinumab, vitiligo and other psoriatic symptoms gradually resolved. After 1 year of treatment, only small plaque areas were present in the flexor site with complete remission in the extensor area along with near complete resolution of depigmented areas. In this case of possible adalimumab-induced vitiligo in a patient with plaque psoriasis, secukinumab resolved both the symptoms of psoriasis and the likely adalimumab-related vitiligo.</jats:p> |
| doi_str_mv | 10.1093/omcr/omz134 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9vbWNyL29tejEzNA |
| imprint | Oxford University Press (OUP), 2020 |
| imprint_str_mv | Oxford University Press (OUP), 2020 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 2053-8855 |
| issn_str_mv | 2053-8855 |
| language | English |
| last_indexed | 2024-03-01T16:01:09.581Z |
| match_str | palazzo2020resolutionofpostadalimumabvitiligowithsecukinumabinapatientwithpsoriasisvulgaris |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | Oxford Medical Case Reports |
| source_id | 49 |
| spelling | Palazzo, Giovanni 2053-8855 Oxford University Press (OUP) Infectious Diseases Microbiology Parasitology http://dx.doi.org/10.1093/omcr/omz134 <jats:title>Abstract</jats:title> <jats:p>Plaque psoriasis is a chronic debilitating condition, and biologic agents that inhibit tumor necrosis factor-α (TNF-α) are widely employed in management of the condition. Notwithstanding, several paradoxical adverse reactions have been reported with TNF-α inhibitors, including vasculitis, vitiligo, alopecia areata, sarcoidosis and other granulomatous diseases. Herein, we report the case of a 63-year-old man who developed vitiligo while on therapy with adalimumab following failure of conventional agents for plaque psoriasis. After discontinuation of adalimumab and initiation of secukinumab, vitiligo and other psoriatic symptoms gradually resolved. After 1 year of treatment, only small plaque areas were present in the flexor site with complete remission in the extensor area along with near complete resolution of depigmented areas. In this case of possible adalimumab-induced vitiligo in a patient with plaque psoriasis, secukinumab resolved both the symptoms of psoriasis and the likely adalimumab-related vitiligo.</jats:p> Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris Oxford Medical Case Reports |
| spellingShingle | Palazzo, Giovanni, Oxford Medical Case Reports, Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris, Infectious Diseases, Microbiology, Parasitology |
| title | Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_full | Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_fullStr | Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_full_unstemmed | Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_short | Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_sort | resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| title_unstemmed | Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris |
| topic | Infectious Diseases, Microbiology, Parasitology |
| url | http://dx.doi.org/10.1093/omcr/omz134 |